Herve Hoppenot - 02 Jan 2026 Form 4 Insider Report for BICYCLE THERAPEUTICS PLC (BCYC)

Reporting relationship: Director
Issuer ticker: BCYC
Reported as of: 02 Jan 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 06 Jan 2026, 20:00:19 UTC
Prior SEC filing: 10 Dec 2025
Next SEC filing: 10 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Travis Thompson, Attorney-in-Fact

Key filing fact

Herve Hoppenot filed Form 4 for BICYCLE THERAPEUTICS PLC (BCYC) on 06 Jan 2026.

Key facts

This page summarizes Herve Hoppenot's Form 4 filing for BICYCLE THERAPEUTICS PLC (BCYC).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 06 Jan 2026, 20:00.

Change

Previous filing in this sequence was filed on 10 Dec 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001596492 Primary reporting owner

Hoppenot Herve

Relationship: Director
Address: C/O BICYCLE THERAPEUTICS PLC, BLOCKS A & B, PORTWAY BUILDING, CAMBRIDGE, UNITED KINGDOM
Signature: /s/ Travis Thompson, Attorney-in-Fact
Signature date: 06 Jan 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

BCYC transaction

Ordinary Shares

Award

Transaction value: $0
Shares: +3,032
Change %: +24%
Price: $0.000000
Shares after: 15,532
Date: 02 Jan 2026
Ownership: Direct
Footnotes: F1, F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

BCYC transaction Derivative

Stock Option (right to buy)

Award

Transaction value: $0
Shares: +6,065
Change %
Price: $0.000000
Shares after: 6,065
Date: 02 Jan 2026
Ownership: Direct
Underlying class: Ordinary Shares
Underlying amount: 6,065
Exercise price: $7.08
Footnotes: F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

Represents a restricted share unit ("RSU") award. The RSUs shall vest in four equal installments on March 15, 2026, June 15, 2026, September 15, 2026 and December 15, 2026.

Footnote F2

Each RSU represents a contingent right to receive one ordinary share.

Footnote F3

This option shall vest in four equal installments on March 15, 2026, June 15, 2026, September 15, 2026 and December 15, 2026.